Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer.
about
A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerPrognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Developing imaging strategies for castration resistant prostate cancer(18)F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.Zibotentan for the treatment of castrate-resistant prostate cancer.Blockade of testicular and adrenal androgens in prostate cancer treatment.Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer.Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.
P2860
Q34657338-F82D0D53-3315-4B7D-B140-048B90B535BEQ35582133-882EDF1B-57EC-49BC-80A0-A7D1C404F398Q36152211-B7201CFC-3A9D-4D33-9D58-CC03B6AFE462Q36502692-8A355159-A34F-41B7-B49A-AA2996F8AC74Q37199286-F10A1EB3-D838-4E43-B781-06E6DCAEC64DQ37760222-0C9B41A0-AE55-4A52-A029-792B1CD0F82FQ37829637-2C79B3EF-4AF3-4C5E-9433-1F32B486CD53Q37974971-362E8274-9A1E-4890-9F21-1154FBD83938Q38438248-2339F7CB-B7A7-4364-8AE0-5C20DC012343Q38749882-29F6F0F5-5A73-4AED-ACB8-35BB61745B3BQ45738696-6360C873-8112-44DA-801A-094E3A4271F5Q48139886-0EEF3448-D605-43C7-8D49-DAEF47C3B5CCQ52982270-116079ED-C98C-4B82-BD1C-B6FA3A392609
P2860
Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Measuring therapeutic efficacy ...... ate-resistant prostate cancer.
@en
Measuring therapeutic efficacy ...... ate-resistant prostate cancer.
@nl
type
label
Measuring therapeutic efficacy ...... ate-resistant prostate cancer.
@en
Measuring therapeutic efficacy ...... ate-resistant prostate cancer.
@nl
prefLabel
Measuring therapeutic efficacy ...... ate-resistant prostate cancer.
@en
Measuring therapeutic efficacy ...... ate-resistant prostate cancer.
@nl
P356
P1476
Measuring therapeutic efficacy ...... ate-resistant prostate cancer.
@en
P2093
J A Schalken
P F Mulders
P2860
P2888
P304
P356
10.1038/PCAN.2009.25
P577
2009-07-14T00:00:00Z